Clinical Trials Logo

IDH Mutation clinical trials

View clinical trials related to IDH Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05345002 Recruiting - Glioma Clinical Trials

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Start date: November 16, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune response.

NCT ID: NCT04955938 Recruiting - Clinical trials for Myeloproliferative Neoplasm

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Start date: October 29, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this research is to gather information on the safety and effectiveness of fedratinib (a drug called a "jak inhibitor" ) in combination with ivosidenib or enasidenib (two anti-cancer drugs). While all three drugs are FDA-approved for various conditions, the US Food and Drug Administration (FDA) has not approved the combination of these drugs for the treatment of rare blood cancers that present Isocitrate dehydrogenase (IDH) mutations, and therefore these drugs can only be given in a research study.

NCT ID: NCT04740190 Recruiting - Clinical trials for Recurrent Glioblastoma

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

TAC-GReD
Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma. Carboplatin will be added to sensitize the tumor to PARP inhibition, and low dose radiation therapy will be applied to increase talazoparib drug penetration through blood-brain barrier. The goal is to estimate the effect size of such combinational treatment approach in recurrent high-grade glioma with DNA damage repair deficiency (dDDR)

NCT ID: NCT04233788 Recruiting - Glioma Clinical Trials

Metabolic Characterization of Space Occupying Lesions of the Brain

FASTMRSI
Start date: September 1, 2021
Phase:
Study type: Observational

High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all sequences, or reduction of measurement times. Recent findings has shown that MRSI can be used to evaluate the isocitrate dehydrogenase (IDH) status of gliomas, a brain tumor type which is most often diagnosed in humans. Patients with IDH-mutated gliomas have a much longer survival time that IDH-wildtype. In IDH-mutated gliomas the substance 2-hydroxy-glutarate (2HG) is found, whereas in IDH-wildtype gliomas it is not. The underlying trial aims to measure 2HG directly with different MRSI sequences at 3 Tesla (3T) and 7 Tesla (7T) magnetic field strength. Apart from MRSI-techniques for IDH-typing it has been shown that CEST-imaging can also be performed to determine the IDH-status of gliomas. A total of 75 patients and 50 healthy controls will be examined in this study to evaluate the most accurate method for pre-operative IDH-status determination.

NCT ID: NCT03991832 Recruiting - Solid Tumor Clinical Trials

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

SOLID
Start date: December 31, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2 study of the combination of drugs olaparib and durvalumab for the treatment of isocitrate dehydrogenase or (IDH) mutated solid tumors. The purpose of this study is to assess the efficacy of the drug combination via overall response rate and overall disease control rate. It is believed that giving olaparib and durvalumab together would be more useful when given to patients with IDH-mutated solid tumors than giving each drug alone.